![FDA says it had no input as companies developed checkpoint inhibitors in China](https://cdn.cancerletter.com/media/2022/02/04143036/48-05-fda-pd1-4x3-1.jpg)
![FDA says it had no input as companies developed checkpoint inhibitors in China](https://cdn.cancerletter.com/media/2022/02/04143036/48-05-fda-pd1-4x3-1.jpg)
Cover Story
White House
By Alice Tracey and Matthew Bin Han Ong
In Brief
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
Clinical Roundup
Drugs & Targets
NCI Trials
![NCI Trials](https://cdn.cancerletter.com/media/2019/05/03161630/CTEP.jpg)
![NCI Trials](https://cdn.cancerletter.com/media/2019/05/03161630/CTEP.jpg)
NCI Trials for February 2022
The National Cancer Institute approved the following clinical research study last month.
Trending Stories
- “All in Her Head” catalogs the history of medicine’s atrocities against women
- CM24 combination improves clinical outcomes in advanced metastatic PDAC in phase II study interim data
- Prominent GI oncologist Axel Grothey was forced out of Mayo Clinic for unethical sexual relationships with women he mentored
Three reprimands later, he retains leadership—and mentorship—positions - Chernobyl: a 35 year follow up on long-term health effects
- How a Georgetown med school student found her calling in surgery, law, and health equity
- The unKOOL, unfiltered history of menthol cigarettes